Yale taps Genesis CRO for drug discovery services

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Sandra Leidholdt)
(Image: Getty/ Sandra Leidholdt)

Related tags: CRO, Drug discovery, Research and development, Research

Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.

The new partnership will bring Genesis Biotechnology Group (GBG) and its contract research organization (CRO) arm, Genesis Drug Discovery & Development (GD3), together with Yale to provide drug discovery services to researchers at the university.

GD3’s service providers include PharmOptima – after an acquisition​ in 2017 – Invivotek, and Venenum Biodesign.

According to William Wiesler, director of new ventures at the office of cooperative research at Yale University, the $25m Blavatnik Fund for Innovation was designed to bridge the gap from life science research to business. The fund will invest up to $300,000 per project to conduct experiments that prospective industry partners view as critical.

“It is the intent of the fund that most of the work be done outside of Yale at highly regarded CRO’s that are trusted by pharmaceutical companies and biotech investors. Genesis Biotech Group was chosen as Yale’s newest partner to provide these services on the basis of their strong reputation, breadth of services, and high-quality engagement with Yale Faculty,” ​said Wiesler.

Yale faculty will be able to, therefore, explore ideas with members of the Genesis Biotech group to develop research plans in collaboration, explained Wiesler.

He also stated that Yale labs have had a number of breakthrough medical products receive approval.

“Yale’s pharmaceutical pipeline boasts five marketed drugs and 20 in clinical development,” ​said Weisler. Partnerships, like that of GBG, are expected to grow the pipeline and advance more projects through preclinical development into trials. 

Related news

Show more

Related products

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars